Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02940860 · ClinicalTrials.gov registry record · Phase 3
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease
A Phase 3 study, sponsored by Pharmacosmos A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,538
- Enrollment target
NCT02940860: Completed Phase 3 study, sponsored by Pharmacosmos A/S.
NCT02940860 is a Phase 3 study that has completed, run by Pharmacosmos A/S. The registered enrollment target is 1,538 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02940860, a Phase 3 study, has completed, sponsored by Pharmacosmos A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,538 participants
- Enrollment target
Study Summary
Evaluation of safety and efficacy of iron isomaltoside/ferric derisomaltose compared with iron sucrose, in subjects with both non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA).
Primary Outcome
Efficacy Evaluate the effect of iron isomaltoside/ferric derisomaltose vs iron sucrose in subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA). Response was defined as change from baseline in hemoglobin (Hb) to week 8, i.e. ability to increase Hb in subjects with NDD-CKD and IDA, when oral iron preparations were ineffective or could not be used, or in whom the Hb measurement at screening in Investigators' opinion were sufficiently low to requi
Interventions
- DRUG Iron sucrose
- DRUG Iron isomaltoside/ferric derisomaltose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,538 participants |
| Start Date | 2016-11-29 |
| Est. Completion | 2018-05-29 |
| Phase | Phase 3 |
What the finished NCT02940860 record still lists
NCT02940860 is an interventional study that assigns participants to a tested intervention. Its 1,538 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% higher).
The record links to 0 conditions, and to 2 interventions - of which Iron sucrose is the first listed.
NCT02940860 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02940860 about?
NCT02940860 is a clinical study titled "Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease". Evaluation of safety and efficacy of iron isomaltoside/ferric derisomaltose compared with iron sucrose, in subjects with both non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA).
What is the current status of trial NCT02940860?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,538 participants. The study started on 2016-11-29. Estimated completion is 2018-05-29.
What interventions are being tested in trial NCT02940860?
The interventions under investigation include: Iron sucrose (DRUG), Iron isomaltoside/ferric derisomaltose (DRUG).
Who is sponsoring clinical trial NCT02940860?
This trial is sponsored by Pharmacosmos A/S, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02940860's enrollment target sits among peer trials
1,538 151st of 2000 higher than 1,849 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06842875 · 1,536 participants · NA
Rhode Island - Statewide Postpartum Hypertension Remote Surveillance
- NCT03435796 · 1,541 participants · Phase 2
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- NCT06729775 · 1,546 participants · NA
Disentangling the Role of Culture, Life Stage, and Information Design to Facilitate Equity in Data Report Back
- NCT06393374 · 1,530 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI